2024-12-09 | Variant classified as varying clinical consequence (low penetrance of CF) on the basis of epidemiological data (in particular high frequency in the general population), the number and type of diagnosis for patients reported in CFTR-France and functional data |
Variant NM_000492.4:c.3454G>C
Name | NM_000492.4:c.3454G>C |
Protein name | NP_000483.3:p.(Asp1152His) |
Genomic name (hg19) | chr7:g.117254753G>C UCSC |
Genomic name (hg38) | chr7:g.117614699G>C UCSC |
#Exon/intron | exon 21 |
Legacy Name | D1152H |
Class | disease-causing |
Subclass | varying clinical consequence |
WT sequence | GCAGTGGGCTGTAAACTCCAGCATA G ATGTGGATAGCTTGGTAAGTCTTAT |
Mutant sequence | GCAGTGGGCTGTAAACTCCAGCATA C ATGTGGATAGCTTGGTAAGTCTTAT |
![]() |
![]() | dbSNP rs75541969 |
![]() | ![]() |
Reference | PMID | Splicing | mRNA level | Maturation | Localization | Channel fonction (Cl-) | Bicarbonate |
Vankeerberghen et al, 1998 | 9804160 | ✓ | ✓ | ||||
Caputo et al, 2009 | 19491324 | ✓ | ✓ | ||||
Van Goor et al, 2014 | 23891399 | ✓ | ✓ | ✓ | |||
Sosnay et al, 2013 | 23974870 | ✓ | ✓ | ||||
LaRusch et al, 2014 | 25033378 | ✓ | ✓ | ✓ |
« ✓ » indicates the type of analysis performed and not the results
Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
IVA | yes | no | no | yes |
TEZ-IVA | yes | yes | no | yes |
ELX-TEZ-IVA | yes | no | yes | no |
clinical and functional data are provided by Vertex
3 individuals carrying this variant are reported in CFTR-NGS catalogue |
TOTAL NUMBER OF PATIENTS | 127 |
---|---|
Asymptomatic compound heterozygote | 4 |
CF | 31 |
CFTR-RD | 81
|
Pending | 3 |
Pending (NBS) | 8 |
Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
Phenotype | Patient ID | Variant status | Additional variants |
---|---|---|---|
CBAVD | 2202 | heterozygote | CF-causing- Undef |
CBAVD | 5047 | heterozygote | varying clinical consequence- Undef |
CBAVD | 5095 | heterozygote | CF-causing- Undef |
CBAVD | 5398 | heterozygote | CF-causing- Undef |
CBAVD | 5459 | heterozygote | varying clinical consequence - Trans |
CBAVD | 6245 | heterozygote | CF-causing- Undef |
CBAVD | 6394 | heterozygote | varying clinical consequence- Undef |
CBAVD | 1968 | heterozygote | CF-causing- Undef |
CBAVD | 2713 | heterozygote | CF-causing- Undef |
CBAVD | 2747 | heterozygote | varying clinical consequence- Undef |
CBAVD | 4562 | heterozygote | CF-causing - Trans |
CBAVD | 4595 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 6473 | heterozygote | VUS3- Undef |
CBAVD | 6479 | heterozygote | CF-causing - Trans |
CBAVD | 4271 | heterozygote | CF-causing- Undef |
CBAVD | 3281 | heterozygote | CF-causing- Undef |
CBAVD | 3309 | heterozygote | CF-causing- Undef |
CBAVD | 3311 | heterozygote | varying clinical consequence- Undef |
CBAVD | 5593 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 8 | heterozygote | CF-causing - Trans |
CBAVD | 498 | heterozygote | CF-causing - Trans |
CBAVD | 541 | heterozygote | CF-causing - Trans |
CBAVD | 544 | heterozygote | CF-causing- Undef |
CBAVD | 612 | heterozygote | CF-causing- Undef |
CBAVD | 697 | heterozygote | VUS3 - Trans |
CBAVD | 737 | heterozygote | CF-causing- Undef |
CBAVD | 897 | heterozygote | CF-causing- Undef |
CBAVD | 990 | heterozygote | CF-causing- Undef |
CBAVD | 492 | heterozygote | CF-causing- Undef |
CBAVD | 4696 | heterozygote | CF-causing- Undef |
CBAVD | 416 | heterozygote | CF-causing- Undef |
CBAVD | 418 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 425 | heterozygote | CF-causing- Undef |
CBAVD | 437 | heterozygote | CF-causing - Trans |
CBAVD | 448 | heterozygote | CF-causing- Undef |
CBAVD | 477 | heterozygote | CF-causing- Undef |
CBAVD | 1509 | heterozygote | likely CFTR-RD- Undef |
CBAVD | 1521 | heterozygote | CF-causing - Trans |
CBAVD | 1616 | heterozygote | varying clinical consequence- Undef |
CBAVD | 1668 | heterozygote | CF-causing- Undef |
CBAVD | 1497 | heterozygote | CF-causing- Undef |
CBAVD | 1490 | heterozygote | VUS3 - Trans VUS1 - Trans |
CBAVD | 1263 | heterozygote | CF-causing - Trans |
CBAVD | 1314 | heterozygote | CF-causing- Undef |
CBAVD | 1368 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 1401 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 1454 | heterozygote | CFTR-RD-causing- Undef |
CBAVD | 1783 | heterozygote | CF-causing- Undef |
Bronchiectasis | 2022 | heterozygote | CF-causing - Trans |
Bronchiectasis | 5112 | heterozygote | CF-causing- Undef |
Bronchiectasis | 5887 | heterozygote | CF-causing- Undef |
Bronchiectasis | 6244 | heterozygote | CF-causing - Trans |
Bronchiectasis | 6273 | heterozygote | CF-causing - Trans |
Bronchiectasis | 4604 | heterozygote | CF-causing- Undef |
Bronchiectasis | 4607 | heterozygote | CF-causing- Undef |
Bronchiectasis | 3213 | heterozygote | CF-causing - Trans CFTR-RD-causing - Trans |
Bronchiectasis | 4678 | heterozygote | CF-causing - Trans |
Bronchiectasis | 5182 | heterozygote | CF-causing- Undef VUS3- Undef |
Bronchiectasis | 1117 | heterozygote | CF-causing- Undef |
Bronchiectasis | 4863 | heterozygote | CF-causing- Undef |
Bronchiectasis | 5707 | homozygote | c.3454G>C - p.(Asp1152His) - Trans |
Pancreatitis | 2110 | heterozygote | CFTR-RD-causing - Trans |
Pancreatitis | 4890 | heterozygote | CF-causing- Undef |
Pancreatitis | 5698 | heterozygote | CFTR-RD-causing- Undef |
Pancreatitis | 4976 | heterozygote | CFTR-RD-causing- Undef |
Pancreatitis | 4692 | heterozygote | CFTR-RD-causing- Undef |
Pancreatitis | 1662 | heterozygote | CF-causing- Undef |
Pancreatitis | 5696 | homozygote | c.3454G>C - p.(Asp1152His) - Trans |
CRS-NP | 4733 | heterozygote | CF-causing- Undef |
CRS-NP | 5537 | heterozygote | CFTR-RD-causing- Undef |
CRS-NP | 6189 | heterozygote | CF-causing- Undef |
CF | 4999 | heterozygote | CF-causing- Undef |
CF | 2088 | heterozygote | CF-causing- Undef |
CF | 2121 | heterozygote | CF-causing- Undef |
CF | 2426 | heterozygote | CF-causing- Undef |
CF | 4895 | heterozygote | CF-causing- Undef |
CF | 4923 | heterozygote | CF-causing- Undef |
CF | 4924 | heterozygote | CF-causing - Trans |
CF | 4952 | heterozygote | CF-causing- Undef |
CF | 2023 | heterozygote | CF-causing- Undef |
CF | 2015 | heterozygote | CF-causing- Undef |
CF | 4605 | heterozygote | CF-causing - Trans |
CF | 4133 | heterozygote | CF-causing - Trans |
CF | 2842 | heterozygote | CF-causing - Trans |
CF | 4035 | heterozygote | CF-causing- Undef |
CF | 4128 | heterozygote | CF-causing - Trans |
CF | 579 | heterozygote | CF-causing - Trans |
CF | 600 | heterozygote | CF-causing- Undef |
CF | 787 | heterozygote | CF-causing - Trans |
CF | 488 | heterozygote | CF-causing - Trans |
CF | 238 | heterozygote | CF-causing - Trans |
CF | 249 | heterozygote | CF-causing - Trans |
CF | 264 | heterozygote | CF-causing- Undef |
CF | 1543 | heterozygote | CF-causing- Undef |
CF | 1545 | heterozygote | CF-causing - Trans |
CF | 1628 | heterozygote | CF-causing- Undef |
CF | 1667 | heterozygote | CF-causing- Undef |
CF | 1728 | heterozygote | CF-causing- Undef |
CF | 1729 | heterozygote | CF-causing- Undef |
CF | 1259 | heterozygote | CF-causing- Undef |
CF | 1279 | heterozygote | CF-causing - Trans |
CF | 4864 | heterozygote | CF-causing- Undef |
Other | 2260 | heterozygote | CF-causing- Undef |
Other | 5369 | heterozygote | CF-causing- Undef |
Other | 4542 | heterozygote | CF-causing - Trans |
Other | 4600 | heterozygote | CF-causing- Undef |
Other | 6190 | heterozygote | CF-causing- Undef |
Other | 6310 | heterozygote | CF-causing- Undef |
Other | 315 | heterozygote | VUS3- Undef |
Other | 4799 | heterozygote | CF-causing- Undef VUS3- Undef |
Other | 1082 | heterozygote | CF-causing - Trans |
Aquagenic palmoplantar keratoderma | 5365 | heterozygote | VUS3- Undef VUS3- Undef |
Pending (NBS) | 4920 | heterozygote | CF-causing - Trans |
Pending (NBS) | 6019 | heterozygote | CF-causing - Trans |
Pending (NBS) | 6482 | heterozygote | CF-causing- Undef |
Pending (NBS) | 3492 | heterozygote | CF-causing- Undef |
Pending (NBS) | 3876 | heterozygote | CF-causing- Undef |
Pending (NBS) | 5805 | heterozygote | CF-causing - Trans |
Pending (NBS) | 1566 | heterozygote | CF-causing - Trans |
Pending (NBS) | 1114 | heterozygote | CF-causing - Trans |
Pending | 1212 | heterozygote | CF-causing - Trans |
Pending | 2132 | heterozygote | varying clinical consequence - Trans |
Pending | 2944 | heterozygote | CF-causing - Trans |
Asymptomatic compound heterozygote | 4564 | heterozygote | CF-causing - Trans |
Asymptomatic compound heterozygote | 2808 | heterozygote | |
Asymptomatic compound heterozygote | 2971 | heterozygote | CF-causing - Trans |
Asymptomatic compound heterozygote | 1574 | heterozygote | CF-causing - Trans |
Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
CFTR variants are clustered into five groups: |
|